Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASCO: Keytruda Inches Uncertainly Towards Tecentriq In Triple-Negative Breast Cancer

KEYNOTE-355 Mixed On PFS; Still Waiting On OS

Executive Summary

Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.

You may also be interested in...



Merck's Keytruda Doubled PFS In Some Colorectal Cancer Patients In ASCO Late-Breaker

Pembrolizumab should be considered the new standard of care as first-line therapy in patients with microsatellite instability high (MSI-H) metastatic colorectal cancer, KEYNOTE-177 investigator André said.

Triple-Negative Breast Cancer First In England As NICE Reverses Tecentriq Rejection

Roche has resolved the issues raised by the health technology assessment body over what is the first immunotherapy approved  for treating this aggressive and difficult-to-treat form of breast cancer.

Roche's Tecentriq Notches Approval For First-Line NSCLC Monotherapy

The company is getting more attention these days for its TIGIT inhibitor tiragolumab in combination with Tecentriq for 1L NSCLC, but a new 1L monotherapy indication for Tecentriq helps it compete against Keytruda. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142222

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel